Clinical trials: Irritable Bowel Syndrome With Constipation
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Fecal Calprotectin Collection Protocol
The primary objective is to obtain stool samples from subjects diagnosed with , and displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study.
- Conditions
- Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease
- Trial name
- CALFE (NCT03143517)
- Testing
- Stool collection
- Where
- 13 sites in United States
- Volunteers
- 240 people
- Sponsor
- DiaSorin Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation
- Trial name
- NCT02493036
- Testing
- SYN-010
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with…
- Trial name
- NCT02495623
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation, Chronic Constipation
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00730171
- Testing
- Linaclotide
- Where
- 116 sites in United States
- Volunteers
- 1,743 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo.
- Trial name
- D5630C00001 (NCT01880424)
- Testing
- Linaclotide
- Where
- 82 sites in United States, Australia and 3 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms
The purpose of this study is to analyse the effect of a probiotic supplement on functional intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS).
- Trial name
- NCT01728610
- Testing
- Probiotic (Active high), Probiotic (Active low)
- Where
- 2 sites in Finland
- Volunteers
- 391 people, healthy volunteers welcome
- Sponsor
- Danisco
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation
This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. The difference of responder rate between test group (10, 20 and 40mg) and placebo will be evaluated.
- Trial name
- YKP (NCT02082457)
- Testing
- YKP10811 5mg, YKP10811 20mg
- Where
- South Korea
- Volunteers
- 273 people
- Sponsor
- SK Chemicals Co., Ltd.
Non-constipation Irritable Bowel Syndrome
Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome
The purpose of this study is to determine the efficacy and safety of different doses of SKI3246 compared with placebo in the treatment of patients with irritable bowel syndrome with non-constipation.
- Trial name
- NCT02079675
- Testing
- SKI3246 Low Dose, SKI3246 High Dose
- Where
- South Korea
- Volunteers
- 279 people
- Sponsor
- SK Chemicals Co., Ltd.
Irritable Bowel Syndrome With Constipation
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).
- Trial name
- NCT00938717
- Where
- 107 sites in United States
- Volunteers
- 805 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide
A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.
- Trial name
- NCT01678781
- Where
- 24 sites in China, Egypt and 2 more
- Volunteers
- 607 people
- Sponsor
- Abbott
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome Characterized by Constipation
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00948818
- Testing
- Linaclotide 290 micrograms
- Where
- 118 sites in United States, Canada
- Volunteers
- 803 people
- Sponsor
- Forest Laboratories
Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
- Trial name
- NCT00171431
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available…
- Trial name
- NCT00511771
- Testing
- Tegaserod
- Sponsor
- Novartis
Constipation
Constipation Associated With Irritable Bowel Syndrome (IBS-C)
Multi-centre, double-blind, randomised, placebo-controlled, parallel group study.
- Trial name
- NCT00796354
- Testing
- MOVICOL, Sugar Pill
- Where
- 21 sites in Czechia, France and 5 more
- Volunteers
- 210 people
- Sponsor
- Norgine
Constipation-Predominant Irritable Bowel Syndrome
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT00607971
- Testing
- Renzapride
- Where
- 126 sites in United States
- Volunteers
- 939 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00215566
- Testing
- DDP733
- Where
- 15 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Dynogen Pharmaceuticals